The FDA approved revisions to the safety labels on several drug products, including regadenoson injection, which is used as a pharmacologic stress agent for radionucleotide myocardial perfusion imaging. The revised label for regadenoson will include information about the drug's potential to cause heart block and hypotension in some patients.

Related Summaries